Please enter the number of seats you would like to purchase for this event and click the add to cart button to continue to the checkout process.
Based on our Pharmacor advisory service entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms Decision Resources is offering an exclusive Pharmacor analyst call entitled Benign Prostatic Hyperplasia: How Will the Discontinuation of Ozarelix and Launches of PRX-302 and NX-1207 Impact the Novel Injectables Landscape for BPH? Because this analyst call features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on February 4, 2010.
Contact us to learn how you can purchase this Pharmacor advisory service and access a recorded playback of this event.
Click here to view the invite.